Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700086 | 0.86 | ADORA1 (0.36) | ALDH1A1RETNR1H2NR1H3 | |
| SCHEMBL16700414 | 0.85 | NR1H2 (0.33) | ALDH1A1NR1H2NR1H3 | |
| SCHEMBL16711396 | 0.84 | BTK (0.35) | ALDH1A1NR1H2NR1H3 | |
| SCHEMBL18625467 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL16711114 | 0.73 | ADORA1 (0.37) | ALDH1A1NR1H2NR1H3 | |
| SCHEMBL28357282 | 0.72 | ELANE (0.36) | RETNR1H2NR1H3 | |
| SCHEMBL16697373 | 0.71 | MAP4K4 (0.35) | ALDH1A1 | |
| SCHEMBL16700456 | 0.71 | ADORA1 (0.36) | ALDH1A1NR1H2NR1H3 | |
| SCHEMBL16711379 | 0.70 | MAP4K4 (0.36) | NR1H2NR1H3 | |
| SCHEMBL16728665 | 0.69 | MAP4K4 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | ALDH1A1 1456/4885RET 805/4885NR1H2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.